- Conditions
- Lung Cancer
- Interventions
- celecoxib, erlotinib hydrochloride
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 3,701
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 3
- States / cities
- Fayetteville, Arkansas • Stanford, California • Philadelphia, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- oral erlotinib and pulsed doses of oral AT-101
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Pertuzumab, Erlotinib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Rancho Mirage, California • Omaha, Nebraska + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 20
- States / cities
- Fresno, California • Hollywood, Florida • Orlando, Florida + 17 more
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
- Interventions
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Interventions
- iC9.GD2.CAR.IL-15 T Infusion
- Biological
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Advanced Non-squamous Non-Small Cell Lung Cancer
- Interventions
- Pemetrexed, Carboplatin, Bevacizumab 7.5 mg/kg, Bevacizumab 15 mg/kg
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois • Harvey, Illinois
- Conditions
- Neoplasms
- Interventions
- PF-04518600, PF-04518600 plus PF-05082566
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Newport Beach, California • Santa Monica, California + 9 more
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- paclitaxel, carboplatin, gefitinib, radiation therapy, laboratory biomarker analysis
- Drug · Radiation · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib, Spartalizumab, Docetaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Interventions
- Osimertinib, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- Davis, California • San Francisco, California • Aurora, Colorado
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 829
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
- Conditions
- Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
- Interventions
- Avelumab, Axitinib, Palbociclib
- Drug
- Lead sponsor
- Worldwide Innovative Network Association
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- La Jolla, California • Sioux Falls, South Dakota
- Conditions
- Breast Carcinoma, Colon Carcinoma, Kidney Carcinoma, Lymphoma, Non-Small Cell Lung Carcinoma, Prostate Carcinoma
- Interventions
- Internet-Based Intervention, Survey Administration
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- ombrabulin (AVE8062), placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 2 more
- Conditions
- NSCLC Stage IV, NSCLC, Stage IIIC
- Interventions
- Primary Immune Response (PIR) test by Biodesix, Inc.
- Diagnostic Test
- Lead sponsor
- Addario Lung Cancer Medical Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- San Carlos, California • Chicago, Illinois
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Discussion, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Docetaxel, Oxaliplatin, Bevacizumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer
- Interventions
- NT-I7, pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- NeoImmuneTech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
- Interventions
- ADCT-502
- Drug
- Lead sponsor
- ADC Therapeutics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Buffalo, New York • New York, New York + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Burbank, California • Duarte, California + 47 more
- Conditions
- Lung Cancer
- Interventions
- ras peptide cancer vaccine, sargramostim
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 17 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung, Metastases
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky